Physician profile
Ramon E Martinez
NPI 1528122918
$14,570.00
in general payments reported to CMS, 2019-2025
35 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,756 · 2020: $230 · 2021: $291 · 2022: $327 · 2023: $274 · 2024: $84.11 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,660 · Food and Beverage: $846 · Consulting Fee: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,660.00 |
| Food and Beverage | $846.29 |
| Consulting Fee | $460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $10,268.81 | 2025 | Austedo Xr |
| Opko Pharmaceuticals, LLC | $1,500.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $312.72 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $269.70 | 2022-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.83 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $165.43 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $157.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $147.10 | 2019-2021 | |
| Lilly USA, LLC | $142.58 | 2019-2021 | |
| Insulet Corporation | $136.87 | 2019-2021 | |
| Livanova USA, INC. | $120.16 | 2022 | |
| Shire North American Group INC | $119.37 | 2019 | |
| Cequr Corporation | $102.56 | 2022-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $102.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $101.74 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $97.72 | 2019 | |
| Amgen INC. | $85.97 | 2019 | |
| Abbvie INC. | $60.92 | 2019-2021 | |
| Corcept Therapeutics | $58.48 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $49.93 | 2021-2025 | Recorlev |
| Beta Bionics, INC. | $45.44 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $43.52 | 2023 | Afrezza |
| Amneal Pharmaceuticals LLC | $40.33 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $38.85 | 2019-2020 | |
| Radius Health, INC. | $22.45 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.41 | 2023 | Jornay Pm |
| Almatica Pharma LLC | $21.09 | 2025 | Loreev Xr |
| Halozyme INC | $20.84 | 2023 | |
| Noven Therapeutics, LLC | $16.24 | 2023 | Xelstrym, Secuado |
| Theratechnologies INC. | $15.51 | 2019 | |
| Valeritas, INC. | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.45 | 2019 | |
| Tandem Diabetes Care, INC. | $13.57 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.88 | 2021 | |
| Allergan, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.